Dr. Behfar Ehdaie

And I had probably a full sheet schema for a clinical trial that probably had like eight rows, six columns, trying to answer four to five questions. And I thought it was just great. And I remember Andrew sitting back in his chair and going, you put a lot of thought in this, but... This is not how I would approach clinical trials.

And it was at that moment, despite my training in epidemiology and my public health degree during my fellowship, I realized the learning curve is quite steep. And from there on, my interest started.

And it was at that moment, despite my training in epidemiology and my public health degree during my fellowship, I realized the learning curve is quite steep. And from there on, my interest started.

And it was at that moment, despite my training in epidemiology and my public health degree during my fellowship, I realized the learning curve is quite steep. And from there on, my interest started.

So, yeah, I mean, your point about trials not accruing or completing is not just a urology problem. It's universal. You know, we know that only 3% of adult cancer patients actually enroll in clinical trials. The vast majority of trials... don't accrue. In prostate cancer and localized disease, for example, we had 11 clinical trials that didn't accrue over the past two decades.

So, yeah, I mean, your point about trials not accruing or completing is not just a urology problem. It's universal. You know, we know that only 3% of adult cancer patients actually enroll in clinical trials. The vast majority of trials... don't accrue. In prostate cancer and localized disease, for example, we had 11 clinical trials that didn't accrue over the past two decades.

So, yeah, I mean, your point about trials not accruing or completing is not just a urology problem. It's universal. You know, we know that only 3% of adult cancer patients actually enroll in clinical trials. The vast majority of trials... don't accrue. In prostate cancer and localized disease, for example, we had 11 clinical trials that didn't accrue over the past two decades.

So we knew this was a formidable challenge. But I also understood that sometimes you have to start with some singles and doubles before you try to hit a home run. And the first part, and throughout this whole conversation, I really hope to share some pearls. And the first pearl was you have to ask an important question.

So we knew this was a formidable challenge. But I also understood that sometimes you have to start with some singles and doubles before you try to hit a home run. And the first part, and throughout this whole conversation, I really hope to share some pearls. And the first pearl was you have to ask an important question.

So we knew this was a formidable challenge. But I also understood that sometimes you have to start with some singles and doubles before you try to hit a home run. And the first part, and throughout this whole conversation, I really hope to share some pearls. And the first pearl was you have to ask an important question.

And important doesn't mean, you know, New England Journal of Medicine featured article important. What important means, it has to be important to stakeholders. And the stakeholders are often our patients. It could be our colleagues or clinicians within the field or specific subspecialty that we're working in. And so understanding what that important question is, is the purpose of mentors.

And important doesn't mean, you know, New England Journal of Medicine featured article important. What important means, it has to be important to stakeholders. And the stakeholders are often our patients. It could be our colleagues or clinicians within the field or specific subspecialty that we're working in. And so understanding what that important question is, is the purpose of mentors.

And important doesn't mean, you know, New England Journal of Medicine featured article important. What important means, it has to be important to stakeholders. And the stakeholders are often our patients. It could be our colleagues or clinicians within the field or specific subspecialty that we're working in. And so understanding what that important question is, is the purpose of mentors.

So spending time with them and asking them, where is the puck going? My earliest trial was in focal therapy. It was very clear when I started that the field was just beginning. However, what we lacked was good prospective data, especially in North America. And so when we sat down to begin writing that trial, it was starting with a question.

So spending time with them and asking them, where is the puck going? My earliest trial was in focal therapy. It was very clear when I started that the field was just beginning. However, what we lacked was good prospective data, especially in North America. And so when we sat down to begin writing that trial, it was starting with a question.

So spending time with them and asking them, where is the puck going? My earliest trial was in focal therapy. It was very clear when I started that the field was just beginning. However, what we lacked was good prospective data, especially in North America. And so when we sat down to begin writing that trial, it was starting with a question.

And the question that we had to answer was, does focal therapy do what it's supposed to do, which is treat the area that we're targeting? And are we able to select those patients? And finally, as we answer that question, how is the patient's quality of life? And to answer that question, I thought we can write the trial. I had mentors to put it together.

And the question that we had to answer was, does focal therapy do what it's supposed to do, which is treat the area that we're targeting? And are we able to select those patients? And finally, as we answer that question, how is the patient's quality of life? And to answer that question, I thought we can write the trial. I had mentors to put it together.

And the question that we had to answer was, does focal therapy do what it's supposed to do, which is treat the area that we're targeting? And are we able to select those patients? And finally, as we answer that question, how is the patient's quality of life? And to answer that question, I thought we can write the trial. I had mentors to put it together.

But immediately right off the bat, I realized the important question needed to include our stakeholders. And because this was a multi-center trial, we brought everyone together at the very early stages, not to share an already written protocol, but to talk about the skeleton and more importantly, make everyone buy in to the outcome measure. And that was the first step.